The RABBIT registry is supported by a joint, unconditional grant from AbbVie, Alfasigma, Amgen, Biocon, Bristol Myers Squibb, ...

Helping Veterans and Families (HVAF), in partnership with the Indiana Department of Veterans Affairs and Workforce ...

Hello, and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host Zacks Small Cap Research, we're very pleased you joined us for our quarterly ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...